Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

26.03.25 14:40 Uhr

Werte in diesem Artikel
Aktien

103,08 EUR 0,48 EUR 0,47%

Indizes

PKT PKT

18.521,5 PKT -1.060,3 PKT -5,41%

16.550,6 PKT -1.050,4 PKT -5,97%

2.600,7 PKT -135,8 PKT -4,96%

1.854,4 PKT -8,4 PKT -0,45%

5.396,5 PKT -274,5 PKT -4,84%

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Gilead Sciences (GILD) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Gilead Sciences is a member of the Medical sector. This group includes 1011 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Gilead Sciences is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for GILD's full-year earnings has moved 4.2% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.Based on the most recent data, GILD has returned 16.8% so far this year. At the same time, Medical stocks have gained an average of 3.6%. As we can see, Gilead Sciences is performing better than its sector in the calendar year.Another Medical stock, which has outperformed the sector so far this year, is AngioDynamics (ANGO). The stock has returned 11.1% year-to-date.In AngioDynamics' case, the consensus EPS estimate for the current year increased 9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Gilead Sciences belongs to the Medical - Biomedical and Genetics industry, which includes 509 individual stocks and currently sits at #76 in the Zacks Industry Rank. This group has gained an average of 4.3% so far this year, so GILD is performing better in this area.In contrast, AngioDynamics falls under the Medical - Instruments industry. Currently, this industry has 84 stocks and is ranked #76. Since the beginning of the year, the industry has moved -2.1%.Investors interested in the Medical sector may want to keep a close eye on Gilead Sciences and AngioDynamics as they attempt to continue their solid performance.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Gilead Sciences und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Gilead Sciences

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Gilead Sciences

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Gilead Sciences Inc.

Wer­bung

Analysen zu Gilead Sciences Inc.

DatumRatingAnalyst
15.06.2020Gilead Sciences kaufenDZ BANK
15.03.2019Gilead Sciences OutperformBMO Capital Markets
03.01.2019Gilead Sciences OutperformOppenheimer & Co. Inc.
26.10.2018Gilead Sciences OverweightBarclays Capital
01.10.2018Gilead Sciences OverweightCantor Fitzgerald
DatumRatingAnalyst
15.06.2020Gilead Sciences kaufenDZ BANK
15.03.2019Gilead Sciences OutperformBMO Capital Markets
03.01.2019Gilead Sciences OutperformOppenheimer & Co. Inc.
26.10.2018Gilead Sciences OverweightBarclays Capital
01.10.2018Gilead Sciences OverweightCantor Fitzgerald
DatumRatingAnalyst
26.07.2018Gilead Sciences NeutralRobert W. Baird & Co. Incorporated
05.10.2017Gilead Sciences PerformOppenheimer & Co. Inc.
09.03.2017Gilead Sciences NeutralUBS AG
29.04.2016Gilead Sciences HoldMaxim Group
14.12.2012Gilead Sciences neutralGoldman Sachs Group Inc.
DatumRatingAnalyst
25.06.2010Gilead Sciences ausgestopptDer Aktionär
22.10.2009Gilead Sciences underperformWedbush Morgan Securities Inc.
10.02.2006Gilead Sciences underweightPrudential Financial
06.12.2005Gilead Sciences underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Gilead Sciences Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen